[The effect of PSMA PET/CT performed in primary staging on the clinical decision].

AIM: Our study aimed to conduct a retrospective statistical analysis of 18F-JK-PSMA-7 PET/CT results in high-risk prostate cancer patients as part of primary staging, to assess how these results influenced the original treatment plan.

METHODS

The study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.

RESULTS

PSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.

CONCLUSION

Broader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.